DE69227693T2 - Hybride cytokine - Google Patents

Hybride cytokine

Info

Publication number
DE69227693T2
DE69227693T2 DE69227693T DE69227693T DE69227693T2 DE 69227693 T2 DE69227693 T2 DE 69227693T2 DE 69227693 T DE69227693 T DE 69227693T DE 69227693 T DE69227693 T DE 69227693T DE 69227693 T2 DE69227693 T2 DE 69227693T2
Authority
DE
Germany
Prior art keywords
cytokines
hybrid
derived
regions
treating conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69227693T
Other languages
English (en)
Other versions
DE69227693D1 (de
Inventor
George Todaro
Timothy Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Application granted granted Critical
Publication of DE69227693D1 publication Critical patent/DE69227693D1/de
Publication of DE69227693T2 publication Critical patent/DE69227693T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
DE69227693T 1991-08-30 1992-08-24 Hybride cytokine Expired - Lifetime DE69227693T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75317891A 1991-08-30 1991-08-30
PCT/US1992/007112 WO1993005169A1 (en) 1991-08-30 1992-08-24 Hybrid cytokines

Publications (2)

Publication Number Publication Date
DE69227693D1 DE69227693D1 (de) 1999-01-07
DE69227693T2 true DE69227693T2 (de) 1999-07-22

Family

ID=25029503

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227693T Expired - Lifetime DE69227693T2 (de) 1991-08-30 1992-08-24 Hybride cytokine

Country Status (9)

Country Link
US (1) US6204364B1 (de)
EP (1) EP0601043B1 (de)
JP (1) JPH06510202A (de)
AT (1) ATE173763T1 (de)
AU (1) AU666866B2 (de)
CA (1) CA2116533A1 (de)
DE (1) DE69227693T2 (de)
NZ (1) NZ244155A (de)
WO (1) WO1993005169A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6171824B1 (en) * 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
WO1994003492A1 (en) * 1992-08-06 1994-02-17 The University Of Melbourne Interleukin-6 variants and uses therefor
US5460810A (en) * 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
EP0746569A4 (de) * 1993-02-03 1999-03-24 Amrad Corp Ltd Rezeptor-bindende determinante des leukämie hemmendenfaktors
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
CA2212006A1 (en) 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
WO1999029720A2 (en) * 1997-12-10 1999-06-17 Zymogenetics, Inc. Mammalian alpha helical protein-1
US6303770B1 (en) 1997-12-10 2001-10-16 Zymogenetics, Inc. Nucleic acids encoding mammalian alpha helical protein-1
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US6329789B1 (en) * 1999-12-21 2001-12-11 Moltech Corporation Methods of charging lithium-sulfur batteries
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP1252192B1 (de) 2000-02-11 2006-08-16 MERCK PATENT GmbH Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
NZ530545A (en) * 2001-07-11 2006-10-27 Maxygen Holdings Ltd Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
EP2322203A3 (de) * 2002-10-29 2011-07-27 Genentech, Inc. Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
AU2003295401B2 (en) * 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
CA2510180C (en) 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP1699822B1 (de) 2003-12-30 2008-04-23 MERCK PATENT GmbH Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ATE544463T1 (de) 2004-11-05 2012-02-15 Univ Northwestern Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
MX2007015156A (es) * 2005-06-01 2008-02-15 Maxygen Holdings Ltd Polipeptidos g-csf pegilados y metodos para la produccion de los mismos.
ATE555125T1 (de) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
EA016429B1 (ru) 2005-12-30 2012-04-30 Мерк Патент Гмбх Антитела против cd19 с пониженной иммуногенностью
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
ATE103932T1 (de) * 1989-08-22 1994-04-15 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.

Also Published As

Publication number Publication date
EP0601043B1 (de) 1998-11-25
NZ244155A (en) 1994-11-25
ATE173763T1 (de) 1998-12-15
AU2500392A (en) 1993-04-05
AU666866B2 (en) 1996-02-29
CA2116533A1 (en) 1993-03-18
EP0601043A1 (de) 1994-06-15
EP0601043A4 (de) 1995-05-10
DE69227693D1 (de) 1999-01-07
US6204364B1 (en) 2001-03-20
JPH06510202A (ja) 1994-11-17
WO1993005169A1 (en) 1993-03-18

Similar Documents

Publication Publication Date Title
DE69227693D1 (de) Hybride cytokine
GR3003067T3 (en) Insecticidal pyrazolines
CS414591A3 (en) Cytokinin synthesis inhibition factor, antagonists thereof and its use
HU911529D0 (en) Mutants of granulocyte colony stimulating factor (g-csf)
IT8153205V0 (it) Apparecchiatura per la suddivisione mista di tavole
MY105344A (en) New sulphonyl compounds
ES8500727A1 (es) Procedimiento para la obtencion de derivados de feniletilamina
DK471386D0 (da) Farmaceutisk komposition til behandling af leukopeni
EP0455271A3 (en) Anti-inflammatory compositions
DK12990D0 (da) Human granulocyt-makrofag-kolonistimulerende faktor og muteiner heraf
IT8519848A0 (it) Disposizione di grappoli di barre di regolazione.
EP0299759A3 (en) Ferroelectric ceramics
DK187785A (da) Chartreusinderivater og salte deraf, fremgangsmaade til fremstillingaf disse og antitumorpraeparater indeholdende saadanne forbindelser
DK0742720T3 (da) Co-indgivelse af interleukin-3-mutantpolypeptider med CSF'er til produktion af hæmatopoietiske celler med multi-afstamning
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
FR2680773B1 (fr) Chariot de manutention dont la stabilite est renforcee par repartition isostatique des charges aux appuis.
AR244690A1 (es) Compuestos con grupos triazol,tetrahidrofurano y fenilo,composicion fungicida que los contiene,procedimiento de preparacion de dichos compuestos y compuestos intermedios utilizados en los mismos.
AU4486589A (en) N-sulfenylated and n-acylated pyrazolines
EP0226259A3 (de) Kationisches Komplex von Technetium-99m
MY105868A (en) Treatment of myelosuppression associated with acquired immune deficiency.
IT8348181A0 (it) Forno per la cottura di ceramica pesante
DE3579568D1 (de) Antisaeurepulver hoher dichte.
ES8308652A1 (es) Bloque condensador electrico perfeccionado.
UA19048A (uk) Стимулятор росту рослиh
IT8053298V0 (it) Tavolo componibile per ufficio

Legal Events

Date Code Title Description
8364 No opposition during term of opposition